WASHINGTON DC. WA, August 29, 2026 — The FDA also authorized revised COVID-19 vaccines for the 2026-27 season for adults and children, including updated shots from Pfizer-BioNTech, Moderna and Novavax-Sanofi. Targeting all three vaccines to the type XFG—the dominant strain in circulation during this year’s flu season. After approval, shipping commenced immediately to pharmacies and clinics.
Panel of Advisers Recommended Update on Strains
The recommendation by the FDA advisory committee in May followed a review of viral surveillance data. 9 out of 10 experts voted to target the JN.1-lineage XFG variant for Autumn 2026. The panel also determined this placement produced the closest alignment with where circulation is projected.
The Vaccines and Related Biological Products Advisory Committee conducted a review of the most recent antigenic characterization data. Human immunogenicity results from previously tested vaccine formulations were also reviewed by members. That recommendation was instrumental in the FDA choosing which mix would go into shots this fall.
The 2026-27 immunization season isn’t far off, and manufacturers said they could have updated doses ready for that time. That timeline mirrored a seasonal cadence of vaccine-with-symptomatic-circulating-strain realignment that has since become familiar. Health officials said having vaccines available early protects more residents before the winter respiratory illness season gets underway.
Approval Covers Higher-Risk Groups
Pfizer-BioNTech—Comirnaty XFG, approved for adults 65+. It also includes anyone between the ages of 5 to 64 with underlying health conditions. That condition would have to increase their risk of severe COVID-19 complications.
The approval came after a supplemental Biologics License Application (sBLA) jointly submitted by Pfizer and BioNTech. Regulators relied on the collective data in support of earlier Cominary formulations. The evidence comprised clinical, nonclinical and real-world information from multiple previous vaccine seasons.
Comirnaty XFG is a nucleoside-modified mRNA vaccine based on BioNTech’s proprietary platform technology. The new formula modifies older versions to more closely resemble circulating SARS-CoV-2 lineages. The new data related directly to the targeted formulation for XFG’s manufacturing and quality.
Vaccine Shows Broad Immune Response
An interim analysis of the nonclinical data also found that the updated shot produced robust immune responses against XFG and related lineages. Those included XFG.1.1, NB.1.8.1 and PQ.17, according to the manufacturers. As yet, over five billion doses of Comirnaty have been given globally.
In a company press release, researchers said the variability in immune response shows that its platform can respond rapidly to changes. Every seasonal update prioritizes the lineage expected to prevail in transmission in months ahead. This approach is similar to the one for updating annual influenza vaccines, officials said.
The officials insisted that effectiveness data from the real world will be gathered this season. Surveillance continues to help regulators determine if additional updates are warranted before next year’s cycle. The FDA said it would continue tracking variant trends this fall and winter.
The new season has different options for the vaccines.
The following four COVID-19 shots are currently authorized for use in the U.S. this fall. These consist of mNEXSPIKE and Spikevax from Moderna, Comirnaty from Pfizer-BioNTech, and a protein-based vaccine from Novavax-Sanofi. Information on eligibility and dosing can be found on the FDA immunization portal.
Using protein-based technology instead of the mRNA platforms used by its rivals, Novavax-Sanofi’s shot provides a third option for patients who choose that approach. It takes longer to make, but it provides flexibility. Each of the three manufacturers indicated that their next-gen vaccines would be available within days after they’ve been approved.
Pharmacies, hospitals and clinics across the country should have the updated vaccines in a matter of days. Health officials recommend patients who are eligible to speak with their doctor about timing before the respiratory illness season reaches its peak, as noted in public health guidelines. Coverage details for the vaccine are mixed and likely to be similar to prior COVID-19 vaccine seasons.
